Skip to content
Pass Duke Elder
Textbook / Chapter 7 / Medical retina

Diabetic retinopathy, maculopathy and screening

Diabetic retinopathy is a disease of the small retinal vessels, and it is the model for every other retinal vascular disease in this chapter. This lesson explains how hyperglycaemia produces each lesion, how the English screening programme grades what it sees, and how proliferative disease and macular oedema are treated under NICE guidance.

9 minute read10 linked questions

How diabetes damages the retina

Diabetic retinopathy is a microangiopathy: a disease of capillaries, the arterioles that feed them and the venules that drain them. Years of hyperglycaemia injure the capillary wall. The earliest structural changes are loss of pericytes (the contractile support cells wrapped around retinal capillaries), thickening of the capillary basement membrane and, later, loss of endothelial cells.

Two things follow, and every sign of the disease belongs to one or the other. The first is leakage. A capillary without pericytes balloons into a microaneurysm and its wall lets plasma through, so the inner blood-retinal barrier (the tight junctions between retinal capillary endothelial cells) fails. Fluid and lipoprotein collect in the retina. The second is occlusion. Capillaries close, the retina they served becomes ischaemic, and ischaemic retina releases vascular endothelial growth factor (VEGF). VEGF makes vessels leakier still and drives new vessel growth.

Leakage at the macula gives maculopathy, which is the common cause of visual loss in type 2 diabetes. Widespread occlusion gives proliferative retinopathy, which blinds through haemorrhage and traction. The main risk factors are the duration of diabetes and poor glycaemic control, then hypertension, nephropathy, dyslipidaemia, puberty and pregnancy.

The lesions and where they sit

The shape of a retinal haemorrhage tells you its depth. Blood in the nerve fibre layer tracks along the axons and looks like a flame. Blood in the deeper, tightly packed layers is confined to a round dot or blot and takes longer to clear.

LesionWhat it isWhere it lies
MicroaneurysmOutpouching of a weakened capillary. The earliest visible sign, a tiny red dotInner nuclear layer
Dot and blot haemorrhageRupture of a microaneurysm or capillaryInner nuclear and outer plexiform layers
Flame haemorrhageBleed from a superficial precapillary arterioleNerve fibre layer
Hard exudateYellow, sharp-edged lipoprotein left behind where leaked fluid is reabsorbed, often in a ring (circinate) around the leakOuter plexiform layer
Cotton wool spotFluffy white patch of swollen axons where axoplasmic flow has stopped at a small infarctNerve fibre layer
Intraretinal microvascular abnormality (IRMA)Dilated shunt vessels between arteriole and venule beside closed capillariesWithin the retina
Venous beadingSausage-like irregularity of vein calibre, a sign of surrounding ischaemiaRetinal veins
The lesions of diabetic retinopathy
3D atlasFlame haemorrhages and cotton wool spots lie in the nerve fibre layer. Microaneurysms, blot haemorrhages and hard exudates lie deeper.

New vessels grow on the optic disc (NVD) or elsewhere (NVE), usually at the edge of ischaemic retina. They grow forwards on to the back of the vitreous, they are fragile, and they bring fibrous tissue with them. Bleeding gives preretinal or vitreous haemorrhage. Contraction of the fibrous tissue gives tractional retinal detachment. New vessels on the iris (rubeosis) can close the drainage angle and cause neovascular glaucoma.

Screening and grading in England

Retinopathy is silent until it bleeds or reaches the fovea, and treatment works best before that, so it suits screening. The NHS Diabetic Eye Screening Programme invites everyone with diabetes aged 12 or over. Pupils are dilated and two digital photographs are taken of each eye. People with gestational diabetes alone are not invited.

Each eye gets a retinopathy grade (R), a maculopathy grade (M) and a photocoagulation grade (P). The grading definitions below are those on gov.uk. The guidance was revised in August 2024 and the page was last amended in December 2025.

GradeMeaningDefining featuresOutcome
R0No retinopathyNo features. Isolated cotton wool spots with no microaneurysm or haemorrhage count as R0Routine recall
R1BackgroundAny microaneurysm or haemorrhage. Venous loops. Exudate or cotton wool spots when other features of retinopathy are presentRoutine recall
R2LPre-proliferative, lower riskAny of: 8 or more blot haemorrhages, venous beading in 1 quadrant, mild IRMA, more than 20 haemorrhages or microaneurysms in 1, 2 or 3 quadrantsDigital surveillance for further imaging
R2HPre-proliferative, higher riskAny of: more than 20 haemorrhages or microaneurysms in each of the 4 quadrants, venous beading in 2 or more quadrants, moderate IRMA in 1 or more quadrantsRoutine referral to hospital
R3AActive proliferativeNVD, NVE, new preretinal or vitreous haemorrhage, new preretinal fibrosis or tractional detachmentUrgent hospital referral
R3SStable treated proliferativeScatter laser scars with stable appearances after discharge from hospitalDigital surveillance
M0No maculopathyNo M1 featureBy R grade
M1Referable maculopathyExudate within 1 disc diameter of the centre of the fovea. A group of exudates within the macula covering half a disc area or more. Any microaneurysm or haemorrhage within 1 disc diameter of the fovea only if acuity is 6/12 or worseRoutine referral to hospital or to a digital surveillance clinic
P0, P1PhotocoagulationP1 means laser scars are present (macular or peripheral)
UUngradableImages cannot be gradedFurther assessment
English screening grades

Three changes are worth knowing. First, R3 was split into R3A and R3S so that treated, stable eyes can be watched outside hospital. Second, a venous loop is no longer referable and now counts as R1. Third, R2 is now divided using the international 4-2-1 rule. Higher-risk R2 (R2H) is more than 20 haemorrhages or microaneurysms in each of the 4 quadrants, venous beading in 2 or more quadrants, or moderate IRMA in 1 or more (moderate means equal to or worse than a standard reference photograph). Any R2 feature short of that is lower-risk R2 (R2L), which goes to digital surveillance for more imaging, to check the peripheral retina, instead of straight to hospital.

Screening was annual for everyone until October 2023. Since then, people whose last two screens both showed no retinopathy are invited every two years, because their chance of developing sight-threatening disease in that interval is very small. Everyone else stays on annual or more frequent recall. Pregnancy accelerates retinopathy, so NICE advises retinal assessment at the first antenatal appointment and again at 28 weeks, with an extra assessment at 16 to 20 weeks if any retinopathy is found at the first.

Maculopathy and macular oedema

Diabetic macular oedema is retinal thickening from leaking microaneurysms and capillaries. It blurs and distorts central vision. Photographs cannot show thickening directly, which is why screening uses exudates and acuity as surrogates. In clinic, optical coherence tomography (OCT) shows the fluid and measures central retinal thickness, and NICE says to use it. A less common form, ischaemic maculopathy, is capillary closure at the fovea. It has no effective treatment.

NICE NG242 (2024) bases treatment on whether the oedema involves the centre of the fovea and on how thick the retina is.

  • Clinically significant oedema that spares the centre: offer macular laser.
  • Centre-involving oedema with good vision: consider macular laser or observation.
  • Centre-involving oedema with visual impairment (6/9 or worse) and central retinal thickness of 400 micrometres or more: offer an intravitreal anti-VEGF drug. NICE-approved options are ranibizumab, aflibercept, faricimab and brolucizumab.
  • Centre-involving oedema with visual impairment and thickness below 400 micrometres: consider anti-VEGF or macular laser.
  • Poor response after 12 months of anti-VEGF, or a person who cannot continue regular injections: consider switching to an intravitreal steroid implant (dexamethasone or fluocinolone acetonide).

Macular laser is aimed at leaking microaneurysms and areas of thickened retina. Anti-VEGF drugs reduce permeability directly. Steroid implants reduce permeability and inflammation, at the cost of cataract and raised intraocular pressure.

Treating proliferative retinopathy

Panretinal photocoagulation (PRP) is the first treatment for most people. Laser burns are scattered across the mid-peripheral and peripheral retina. Destroying ischaemic outer retina lowers the eye's oxygen demand and its VEGF output, so the new vessels regress. The peripheral retina is sacrificed to protect the macula. NICE says to start within 4 weeks of offering it where possible, and on the same day for eyes with high-risk characteristics, such as large disc new vessels, or disc new vessels of any size with preretinal or vitreous haemorrhage.

  • Side effects of PRP: constricted visual field, poorer night vision and contrast sensitivity, and new or worse macular oedema.
  • Anti-VEGF: offered if disease stays active after complete PRP, and considered as a temporary measure when vitreous haemorrhage or cataract prevents laser.
  • Vitrectomy: considered for vitreous haemorrhage that has not cleared within 3 months, and offered for tractional detachment that involves or threatens the macula.

Systemic control

No eye treatment replaces control of the diabetes. In the UK Prospective Diabetes Study each 1% fall in mean HbA1c was associated with a 37% fall in microvascular complications. Treating hypertension slows progression of non-proliferative retinopathy, but NICE says not to give antihypertensives to people with normal blood pressure for this purpose alone. Ophthalmologists should consider fenofibrate (off-label) for people with type 2 diabetes and non-proliferative retinopathy to slow progression.

Summary

  • Diabetic retinopathy is a capillary disease: pericyte loss and basement membrane thickening lead to leakage and to capillary closure.
  • Ischaemic retina releases VEGF, which causes both macular oedema and new vessels.
  • Dot and blot haemorrhages and hard exudates are deep (inner nuclear and outer plexiform layers); flame haemorrhages and cotton wool spots are in the nerve fibre layer.
  • English grades are R0 none, R1 background, R2 pre-proliferative (split into lower-risk R2L and higher-risk R2H), R3A active proliferative, R3S stable treated, M0 or M1 for the macula, and P1 for laser scars.
  • M1 is exudate within one disc diameter of the fovea, a group of exudates in the macula, or a microaneurysm or haemorrhage within one disc diameter with acuity of 6/12 or worse.
  • Screening starts at age 12 and, since October 2023, is every two years for people with two consecutive screens showing no retinopathy.
  • Panretinal photocoagulation is first-line treatment for proliferative retinopathy; anti-VEGF and vitrectomy are used when laser is not enough or not possible.
  • Centre-involving macular oedema with visual impairment and thickness of 400 micrometres or more is treated with anti-VEGF injections; steroid implants are second line.
  • Glycaemic and blood pressure control slow retinopathy, but a rapid fall in HbA1c can cause early worsening.

Check yourself

Quick recall on this lesson. These are easier than the question bank.

1. In which retinal layer do hard exudates lie?
2. A screening image shows new vessels on the optic disc in an eye never treated before. What is the grade?
3. Who is invited for diabetic eye screening every two years in England?
4. What is the usual first treatment for newly diagnosed proliferative diabetic retinopathy?
Practise 10 questions on this lesson

Written for revision. It is not a source of clinical advice, and guidance changes.